Author:
Paar David P.,Pollard Richard B.
Reference20 articles.
1. Shepp DH, Dandliker PS, Miranda P, et al. “Activity of 9-[2-Hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the Treatment of Cytomegalovirus Pneumonia.” Annals of Internal Medicine. 1985; 103: 368–373.
2. Grundy, J. “Virologie and Pathogenetic Aspects of Cytomegalovirus Infections.” Reviw of Infectious Diseases. 1990; 12 (Suppl. 7): S711–9.
3. Meyers JD, Floumoy N, Thomas ED. “Risk Factors for Cytomegalovirus Infection after Human Marrow Transplantation.” Journal of Infectious Diseases. 1986; 153: 478–88.
4. Bratanow NC, Ash RC, Turner PA, et al. “Successful Treatment of Serious Cytomegalovirus Disease with 9 (1,3-dihydroxy-2-propoxymethyl) Guanine in Bone Marrow Transplant Patients. Blood. 1986;68 Suppl. 1: 280a
5. Emanual D, Cunningham I, Jules-Eleysee K, et al. “Cytomegalovirus Pneumonia after Bone Marrow Transplantation Successfully Treated with the Combination of Ganciclovir and High-Dose Intravenous Immune Globulin.” Annals of Internal Medicine. 1988; 109: 777–82.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recombinant TLR5 Agonist CBLB502 Promotes NK Cell-Mediated Anti-CMV Immunity in Mice;PLoS ONE;2014-05-30
2. Passive Immunization;Primary Care: Clinics in Office Practice;2011-12
3. Therapeutic Use of Immunoglobulins;Advances in Pediatrics;2010-01
4. PASSIVE IMMUNIZATION;Feigin and Cherry's Textbook of Pediatric Infectious Diseases;2009
5. Herpesviral Fcγ receptors: culprits attenuating antiviral IgG?;International Immunopharmacology;2004-09